Literature DB >> 7542828

Tumor necrosis factor alpha but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis.

A Głabiński1, M Mirecka, L Pokoca.   

Abstract

The cytotoxic cytokines tumor necrosis factor alpha (TNF-alpha) and lymphotoxin (LT) possess toxic activity against myelin and/or oligodendrocytes in vitro. Multiple sclerosis (MS) plaques within the central nervous system (CNS) are infiltrated by peripheral blood mononuclear cells (PBMC). In this study the production of TNF-alpha and LT by PBMC in active MS were measured. PBMC were isolated from the blood of MS patients in relapse and also patients with other neurological diseases (OND) and healthy controls (HC). Isolated cells were cultured unstimulated or stimulated with phytohemagglutinin A (PHA), lipopolysaccharide (LPS) and myelin basic protein (MBP)--a hypothetical autoantigen for MS. Cytokine production was assessed using ELISA method. In the MS group, PBMC without stimulation as well as after stimulation with MBP displayed a significantly increased production of TNF-alpha. LT production was similar in MS and control groups. These results suggest that TNF-alpha but not LT is overproduced by PBMC during MS relapse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542828     DOI: 10.1111/j.1600-0404.1995.tb07004.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Soluble Tumor Necrosis Factor Receptor 1 Released by Skin-Derived Mesenchymal Stem Cells Is Critical for Inhibiting Th17 Cell Differentiation.

Authors:  Fang Ke; Lingyun Zhang; Zhaoyuan Liu; Sha Yan; Zhenyao Xu; Jing Bai; Huiyuan Zhu; Fangzhou Lou; Wei Cai; Yang Sun; Yuanyuan Gao; Hong Wang; Honglin Wang
Journal:  Stem Cells Transl Med       Date:  2016-01-27       Impact factor: 6.940

2.  Interleukin 17A Promotes Lymphocytes Adhesion and Induces CCL2 and CXCL1 Release from Brain Endothelial Cells.

Authors:  Dagmara Weronika Wojkowska; Piotr Szpakowski; Andrzej Glabinski
Journal:  Int J Mol Sci       Date:  2017-05-08       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.